Literature DB >> 11895757

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.

James Z Huang1, Warren G Sanger, Timothy C Greiner, Louis M Staudt, Dennis D Weisenburger, Diane L Pickering, James C Lynch, James O Armitage, Roger A Warnke, Ash A Alizadeh, Izidore S Lossos, Ronald Levy, Wing C Chan.   

Abstract

Recently we have identified subgroups of de novo primary diffuse large B-cell lymphoma (DLBCL) based on complementary DNA microarray-generated gene expression profiles. To correlate the gene expression profiles with cytogenetic abnormalities in these DLBCLs, we examined the occurrence of the t(14;18)(q32;q21) in the 2 distinctive subgroups of DLBCL: one with the germinal center B-cell gene expression signature and the other with the activated B cell-like gene expression signature. The t(14;18) was detected in 7 of 35 cases (20%). All 7 t(14;18)-positive cases had a germinal center B-cell gene expression profile, representing 35% of the cases in this subgroup, and 6 of these 7 cases had very similar gene expression profiles. The expression of bcl-2 and bcl-6 proteins was not significantly different between the t(14;18)-positive and -negative cases, whereas CD10 was detected only in the group with the germinal center B-cell expression profile, and CD10 was most frequently expressed in the t(14;18)-positive cases. This study supports the validity of subdividing DLBCL into 2 major subgroups by gene expression profiling, with the t(14;18) being an important event in the pathogenesis of a subset of DLBCL arising from germinal center B cells. CD10 protein expression is useful in identifying cases of DLBCL with a germinal center B-cell gene expression profile and is often expressed in cases with the t(14;18).

Entities:  

Mesh:

Year:  2002        PMID: 11895757     DOI: 10.1182/blood.v99.7.2285

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction.

Authors:  Sharon L Barrans; Paul A S Evans; Sheila J M O'Connor; Roger G Owen; Gareth J Morgan; Andrew S Jack
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

2.  Two newly characterized germinal center B-cell-associated genes, GCET1 and GCET2, have differential expression in normal and neoplastic B cells.

Authors:  Zenggang Pan; Yulei Shen; Cheng Du; Guimei Zhou; Andreas Rosenwald; Louis M Staudt; Timothy C Greiner; Timothy W McKeithan; Wing C Chan
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

3.  Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component.

Authors:  Tiemo Katzenberger; German Ott; Thomas Klein; Jörg Kalla; Hans Konrad Müller-Hermelink; M Michaela Ott
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

4.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.

Authors:  Madhavi Challa-Malladi; Yen K Lieu; Olivia Califano; Antony B Holmes; Govind Bhagat; Vundavalli V Murty; David Dominguez-Sola; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

5.  Incidence of diffuse large B-cell lymphoma of germinal center B-cell origin in whole diffuse large B-cell lymphoma: tissue fluorescence in situ hybridization using t(14;18) compared with immunohistochemistry.

Authors:  Yuko Hirose; Yasufumi Masaki; Hiromi Karasawa; Kumiko Shimoyama; Toshihiro Fukushima; Hiroshi Kawabata; Noriyoshi Ogawa; Yuji Wano; Mamoru Ozaki
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

6.  Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B-cell lymphomas.

Authors:  Weiyi Chen; Jane Houldsworth; Adam B Olshen; Gouri Nanjangud; Seeta Chaganti; Ennapadem S Venkatraman; Jeffrey Halaas; Julie Teruya-Feldstein; Andrew D Zelenetz; R S K Chaganti
Journal:  Blood       Date:  2005-11-29       Impact factor: 22.113

7.  Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Authors:  Silvia Bea; Andreas Zettl; George Wright; Itziar Salaverria; Philipp Jehn; Victor Moreno; Christof Burek; German Ott; Xavier Puig; Liming Yang; Armando Lopez-Guillermo; Wing C Chan; Timothy C Greiner; Dennis D Weisenburger; James O Armitage; Randy D Gascoyne; Joseph M Connors; Thomas M Grogan; Rita Braziel; Richard I Fisher; Erlend B Smeland; Stein Kvaloy; Harald Holte; Jan Delabie; Richard Simon; John Powell; Wyndham H Wilson; Elaine S Jaffe; Emili Montserrat; Hans-Konrad Muller-Hermelink; Louis M Staudt; Elias Campo; Andreas Rosenwald
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

Review 8.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

Review 9.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

10.  BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma.

Authors:  Samantha L Kendrick; Lucas Redd; Andrea Muranyi; Leigh A Henricksen; Stacey Stanislaw; Lynette M Smith; Anamarija M Perry; Kai Fu; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Randy D Gascoyne; Elaine S Jaffe; Elías Campo; Jan Delabie; Rita M Braziel; James R Cook; Raymond R Tubbs; Louis M Staudt; Wing Chung Chan; Christian Steidl; Thomas M Grogan; Lisa M Rimsza
Journal:  Hum Pathol       Date:  2014-06-26       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.